← All trials
NCT05001373
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2021
- Primary completion
- Apr 11, 2023
- Completion date
- Apr 11, 2023
- First posted
- Aug 11, 2021
- Last posted
- Sep 30, 2021
- Enrollment
- 56
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International AIDS Vaccine InitiativeLead sponsor
- University of WashingtonCollaborator
- University of Texas, San AntonioCollaborator
- Emory UniversityCollaborator
- George Washington UniversityCollaborator
- Moderna TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.